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This issue of BJC presents the revised ‘Guidelines for the welfare of
animals in cancer research’ as issued by the National Cancer
Research Institute (Workman et al, 2010). The previous efforts
were published in 1988, and reissued in 1998 under the sponsor-
ship of the United Kingdom Co-coordinating Committee on
Cancer Research (UKCCCR) (Workman, 1988; Workman et al,
1998). These revised guidelines represent an evolution in animal
use guidelines that build on and adapt to the exponential growth in
scientific technique and methodology seen in cancer research
over the past two decades. The use of animals for experimental
investigation as an essential part of scientific enquiry has always
been a significant component of medical history. Indeed, some of
the earliest references for the use of animals for medical research
are found in Greek writings of the second and fourth centuries BCE
(Aristotle; 384–322 BCE and Erasistratus; 304–258 BCE) (Cohen
and Loew, 1984). At present, animal use remains an essential part
of medical science, leading to new insights into the mechanism of
disease, genomic susceptibility, and new developments in diag-
nostics and therapy. There is also the widespread recognition
of the ethical and moral imperative to conduct this research work,
with the highest standards seeking to balance the desire for
scientific clarity with a major emphasis on the concern for animal
welfare. The revised ‘Guidelines for the Welfare and Use of
Animals in Cancer Research’ published in this issue is a direct
outgrowth of this recognition.
Historically, cancer has earned a reputation as a deadly disease
accompanied by pain and suffering in humans. Although medical
science has made great strides in the prevention and treatment of
cancer, it still remains that one in three individuals in the
developed world will develop some form of cancer in their lifetime.
In the pursuit to alleviate this condition in our species, oncological
research makes use of the full panoply of technological tools
available to elucidate the signs and symptoms, causes, patho-
physiology, diagnostic insights, treatment, and epidemiology of
cancer. Yet, despite the substantive advancements in the use of
in vitro models, we do not have a fully effective alternative to the
use of in vivo study for the examination of the fundamental
processes of this disease in living organisms.
Virtually every important medical achievement in the twentieth
century has relied on the use of animals in some way (The Royal
Society, 2004). Oncology research has a similar history, with the
discovery of some 24 significant biomedical advances in the past
30 years that would likely not have occurred without animal
experimentation (Frankie, 2005). However, it is abundantly clear
that this research effort can be conducted effectively in such a
manner as to reduce the adverse effects on animals to a minimum.
The revised ‘Guidelines for the Welfare and Use of Animals in
Cancer Research’ provide the framework for the maintenance of
the highest standards of scientific enquiry in conjunction with
concern for the welfare of the subjects used in this endeavour.
The fundamental problem of animal welfare in cancer research
lays in its inherent dichotomy. Animal models are developed to
test the efficacy of potential life-saving agents against a painful and
fatal disease, cancer. The inherent discordance from an animal
welfare prospective is that animals must be exposed to this disease
in some manner to provide a model of the mechanisms of the
progression of cancer in humans. Yet, without laboratory animals
(especially athymic mice; B95% of all animal studies are
conducted in mice), cancer researchers would lose a fundamental
method for obtaining data required to make appropriate decisions
about potential new therapies that would have enormous impact in
human populations.
The key principles that have served to provide a framework for
subsequent legislative and scientific efforts in guiding animal use
in laboratory research were first published by Russell and Burch
(1959). Their postulation of the ‘Principles of Humane Experi-
mental Techniques’ argued that the adoption of the ‘3Rs’ (Replace,
Reduce, or Refine) should be an integral component of scientific
planning and execution in all studies involving in vivo animal use.
In the opinion of Goldberg and Locke (2004), ‘Humane science
based on the principles of the 3Rs can mean better scientific
results’. The standard rodent models for carcinoma used for the
past 30 years to optimise therapy in humans consist of either s.c.
xenograft or orthotropic implantation of human tumour cells into
athymic mice. These models have several characteristics that make
them good testing systems, including defined and reproducible
location of tumour formation, rate of tumour growth, and
progression of disease (Finkelstein et al, 1994). Following one of
the tenets of the 3Rs (Russell and Burch, 1959), refinement, several
laboratories have developed genetically and histologically accurate
models of carcinoma by gain-of-function (transgenic) approaches
and targeted deletion (including tissue-specific) strategies.
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targeted gene in all cells that would normally express it (Macleod
and Jacks, 1999). These are gene-manipulated ‘extra-evolutionary
species’ of mice bred for medical/scientific purposes.
An example of the influence of another tenet of the 3Rs,
replacement, is the recent development of the ‘Biobank’ (BC,
Canada) as a repository for the transfer of bio-specimens (tissues,
blood, body fluids) and related data that can serve as an interface
between researchers seeking bio-specimens and clinical data
related to different aspects of disease progression (Watson et al,
2009). The establishment of similar biobanks of human biopsy
tissue coupled with clinical data is accelerating throughout the
world and holds the promise of yielding translational discoveries
in areas such as novel molecular and gene targets and candidate
protein biomarkers of disease progression and outcome.
The last of the 3Rs, reduction, is reflected in the development of
scientific methodologies that minimise the number of experimental
animals required to provide sufficient statistical power and seek to
maximise the data obtained from each individual life. In many
European countries including the United Kingdom, such efforts
have witnessed a decline in animal use by 420% between 1991 and
2002 (Frank, 2008). One of the major alternatives to in vivo
modelling is the development of ‘in silico’ computer simulation. It is
encouraging and worth noting, that in silico modelling has shown
some promise as another potential tool in understanding the
underlying mechanisms of tumour biology and the development of
predictions of tumour response to different drugs (such as cisplatin
and doxorubicin). Pharmacokinetics and pharmacodynamics of
early-stage compounds are increasingly being modelled using
computer simulations because of its ability to integrate phenomena
such as vascular extravasation of oxygen and drugs, interstitial
diffusion, and cellular response to local concentrations in spatially
multidimensional settings (Sanga et al, 2006; Sinek et al, 2009).
However, despite these in silico advances, they are not yet able to act
as complete alternatives to in vivo animal experimentation due to
the fact that the simulations cannot examine the entire ‘chemical
space’ of living complex organisms (Lipinski and Hopkins, 2004). At
present, sophisticated computer simulations, while improving at an
exponential rate, are unable to model the myriad of interactions
between molecules, cells, tissues, organs, and the environment,
leaving animal research a necessary component of oncology
research (Committee to Update Science, 2004). Having said that,
‘in silico computer simulation’ can reduce animal usage for testing
of new chemical entities with large combinatorial libraries As we are
still far from an ‘in silico mouse’, the choice for testing anticancer
drugs remains with in vitro, ex vivo, in silico computer simulation
and meticulously designed in vivo models.
The incidence of cancer is projected to increase worldwide
(Boyle, 1997). Thus, there is immense social and economic
pressure to develop new and more efficacious anticancer therapies.
Cancer research is a global enterprise, with medical and scientific
enquiries occurring in a wide range of jurisdictions around the
world, each with their own regulatory mandates and concerns. As
scientific progress will continue at an accelerated pace in cancer
research, it would be expected that consensual and enforceable
ethical guidelines would continue to evolve for the betterment of
this research with due respect to laboratory animal use. Given that
animal experimentation will, for the time being, remain indis-
pensable in cancer/biomedical research, then the application of
principles towards the minimal use of experimental animals
following the 3Rs (Russell and Burch, 1959) will continue to serve
as an accepted framework to ensure that the welfare of animals in
cancer research is protected. The ‘Guidelines for the Welfare of
Animals in Cancer Research’ (Workman et al, 2010) published in
this issue is a continuation of this evolution. Taking into account
the continuous advancement of medical technologies and new
methodologies, the revised Guidelines provide current and future
investigators, governmental regulatory agencies, and pharmaceu-
tical industry with the necessary information to ensure that their
research activities follow the highest possible standards of animal
welfare that is consistent with not only ethical and moral
imperatives but also good scientific practice.
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